Products with Anti-hyperlipidemic Bioactivity

Explore BioCrick products associated with Anti-hyperlipidemic biological activity, including catalog numbers, product names and available bioactivity information.

Cat. No.	Product Name
BCN1287	Hyodeoxycholic acid
Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells. Hyodeoxycholic acid has hypolipidemic effect through regulation of FXR activation, it is a candidate for antiatherosclerotic drug, by significantly increasing the expression of genes involved in cholesterol efflux, such as Abca1, Abcg1,and Apoe,in a macrophage cell line.
BCN1427	Deacetylasperulosidic acid methyl ester
Ddeacetylasperulosidic acid methyl ester can lower the blood glucose level in normal mice.
BCN1635	Iriflophenone 3-C-beta-D-glucopyranoside
1. Iriflophenone-3- C -glucoside has antioxidant activity, it presents no radical scavenging ability against DPPH , but scavenges ABTS + and peroxyl radicals (TEAC ABTS of 1.04 and TEAC ORAC of 3.61). 2. Iriflophenone-3-C-β-d-glucoside shows potent inhibitory activity against α-glucosidase. 3. Iriflophenone 3-C-β-D-glucoside and mangiferin which along with 3 β taraxerol and other sterols could be contributing to the cholesterol lowering activity.
BCN1715	beta-Amyrin acetate
1. beta-Amyrin acetate and β-amyrin palmitate as antidyslipidemic agents, they show significant HMG-CoA-reductase inhibition. 2. beta-Amyrin acetate and honokiol exhibit sEH inhibitory activity. 3. beta-Amyrin acetate has a high antioxidant potential with an IC50 value of 158.2ug/mL, and has cytotoxicity , it could be a viable source of antioxidant and cytotoxic agents in cancer chemotherapy in the near future. 4. beta-Amyrin acetate has anti-inflammatory activity,with ID50 values in the range of 0.15-0.75 micromol/ear. 5. beta-Amyrin acetate exhibits weak-moderate antiproliferative activity against the A2780 human ovarian cancer cell line.
BCN2180	Ezetimibe
1. Ezetimibe is known as a Niemann-Pick C1-Like 1 (NPC1L1) inhibitor and has been used as an agent for hypercholesterolemia, Ezetimibe and simvastatin are equipotent in lowering lipid levels in hypercholesterolemic patients with coexisting PCOS. 2. Ezetimibe administration can improve glycemic control and increase glucagon like peptide-1 (GLP-1), an incretin hormone with anti-diabetic properties, a possible novel biological role of Ezetimibe in glycemic control to stimulate intestinal GLP-1 secretion via the MEK/ERK signaling pathway.

Anti-hyperlipidemic Bioactivity Products